LifeStance Health Group Q3 2026 earnings

LFST · 2026-11-04 19:56 AMC ET · 8-K on SEC

Revenue and Adjusted EBITDA grew 25% and 70% respectively, with Center Margin rising 38% to 35.4% of revenue.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$455.9 million+25.0%+4.7%Ex. 99.1, income statement
EPS (GAAP)$0.06+$0.06+$0.00Ex. 99.1, income statement
EPS (adjusted)NM——Ex. 99.1, income statement
Net income$22.4 million+$21.3 million-$1.2 millionEx. 99.1, income statement
Adj. EBITDA$68.4 million+28.2 million+2.4 millionEx. 99.1, income statement
Adj. EBITDA margin15.0%+3.9 pp-0.2 ppEx. 99.1, income statement

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin not stated in the 8-K
  • Operating expenses $422.8 million (+18.6% YoY)
  • One-offs in the quarter Loss on remeasurement of contingent consideration: $2.3 million; Transaction costs: $0.5 million; Executive transition costs: $0.0 million; Litigation costs: $0.0 million; Strategic initiatives: $1.7 million; Real estate optimization and restructuring charges: $0.0 million
  • Effective tax rate 22.4% (prior-year 76.4%, year-to-date 19.3%)
  • Non-GAAP bridge Adds back interest expense, depreciation and amortization, income tax provision, loss on remeasurement of contingent consideration, stock-based compensation, loss on disposal of assets, transaction costs, executive transition costs, litigation costs, strategic initiatives, real estate optimization and restructuring charges, and amortization of cloud-based software implementation costs.

KPIs

MetricActualPrior quarterPrior yearChange
Clinician base8,8638,5427,992+321 net increase
Visit volumes2.7 million2.6 million2.3 million+17% YoY
Center Margin$161.4 million$153.0 million$116.6 million+38% YoY
Free Cash Flow$22.4 million$87.9 million$6.2 million+260% YoY

Guidance

MetricGuidePrior guideChange
Full year 2026 Revenue$1.741B - $1.761B$1.685B - $1.725B+$56M - $36M
Full year 2026 Center Margin$599M - $613M$570M - $594M+$29M - $19M
Full year 2026 Adjusted EBITDA$242M - $250M$215M - $235M+$27M - $15M
Q4 2026 Revenue$446M - $466M——
Q4 2026 Center Margin$149M - $163M——
Q4 2026 Adjusted EBITDA$56M - $64M——

What drove it

  • Revenue story Revenue grew 25% to $455.9 million, driven by higher visit volumes, net clinician growth, improved clinician productivity, and higher total revenue per visit.
  • EPS story Net income of $22.4 million was driven by higher revenue and improved operating leverage, with a tax rate of 22.4%.
  • One-off check Loss on remeasurement of contingent consideration ($2.3M) and transaction costs ($0.5M) are one-time items.

The good

  • Revenue growth of 25% YoY
  • Adjusted EBITDA of $68.4 million (+70% YoY)
  • Center Margin of $161.4 million (+38% YoY)
  • Raised full year 2026 guidance across all metrics

The bad

  • Free Cash Flow of $22.4 million, down from $87.9 million in Q2 2026
  • Cash and cash equivalents decreased to $218.8 million

The ugly

  • none

Open questions

  • The reconciliation for forward-looking Q4 2026 and full year 2026 Center Margin, Adjusted EBITDA guidance and Free Cash Flow is not provided.
  • The release does not disclose the specific revenue mix by geography or specialty.
Full release

LifeStance Health Group (LFST) earnings release, November 5, 2026

LifeStance Health Group, Inc. (LFST) · Form 8-K, Item 2.02 · Filed · SEC filing

Investor Relations Contact

Monica Prokocki

VP of Finance & Investor Relations

602-767-2100 investor.relations@lifestance.com

LifeStance Reports Strong Third Quarter 2026 Financial Results and Raises Full Year Outlook

SCOTTSDALE, Ariz. – November 5, 2026 – LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation’s largest providers of outpatient mental healthcare, today announced financial results for the third quarter ended September 30, 2026.

(All results compared to prior-year comparative period, unless otherwise noted)

Q3 2026 Highlights and FY 2026 Outlook

• Revenue of $455.9 million increased 25% compared to revenue of $363.8 million

• Clinician base increased 11% to 8,863 clinicians, a sequential net increase of 321 in the third quarter

• Third quarter visit volumes increased 17% to 2.7 million

• Net income of $22.4 million compared to net income of $1.1 million

• Adjusted EBITDA of $68.4 million compared to Adjusted EBITDA of $40.2 million

• Net cash provided by operations of $37.0 million in the third quarter

• Free Cash Flow generation of $22.4 million in the third quarter

• For full year 2026, raising revenue expectations to $1.741 billion to $1.761 billion, Center Margin expectations to $599 million to $613 million, and Adjusted EBITDA expectations to $242 million to $250 million

“The team delivered a tremendous quarter, with execution across the business driving results that once again exceeded our expectations,” said Dave Bourdon, CEO of LifeStance. “The strong momentum gives us the confidence to further raise our full-year 2026 outlook across all financial metrics, while our positive patient outcomes, most recently across TMS and Spravato, reflect our commitment to clinical excellence. At the same time, the investments we are making in our platform, including the implementation of our new EHR, are positioning LifeStance for continued success and scale over the long term.”

NM - not meaningful

(All results compared to prior-year period, unless otherwise noted)

• Revenue grew 25% to $455.9 million. Revenue growth in the third quarter was driven primarily by higher visit volumes from net clinician growth, improved clinician productivity, and higher total revenue per visit.

• i ncome from operations was $33.1 million and net income was $22.4 million.

• Center Margin grew 38% to $161.4 million, or 35.4% of total revenue.

• Adjusted EBITDA increased 70% to $68.4 million, or 15.0% of total revenue. Adjusted EBITDA as a percentage of revenue increased in the third quarter as a result of higher total revenue per visit, lower center costs as a percentage of revenue, and improved operating leverage from revenue growing faster than general and administrative expenses.

Balance Sheet, Cash Flow, and Capital Allocation

For the nine months ended September 30, 2026, LifeStance generated $170.0 million of cash flow from operations, including $37.0 million during the third quarter of 2026. The Company ended the third quarter with cash and cash equivalents of $218.8 million and net long-term debt of $255.5 million.

2026 Guidance

LifeStance is providing the following outlook for 2026:

• The Company is raising full year revenue to $1.741 billion to $1.761 billion, Center Margin to $599 million to $613 million, and Adjusted EBITDA to $242 million to $250 million.

• For the fourth quarter of 2026, the Company expects total revenue of $446 million to $466 million, Center Margin of $149 million to $163 million, and Adjusted EBITDA of $56 million to $64 million.

Conference Call, Webcast Information, and Presentations

LifeStance will hold a conference call today, November 5, 2026 at 8:30 a.m. Eastern Time to discuss the third quarter 2026 results. Investors who wish to participate in the call should dial 1-800-715-9871, domestically, or 1-646-307-1963, internationally, approximately 10 minutes before the call begins and provide conference ID number 3056663 or ask to be joined into the LifeStance call. A real-time audio webcast can be accessed via the Events and Presentations section of the LifeStance Investor Relations website (https://investor.lifestance.com), where related materials will be posted prior to the conference call.

About LifeStance Health Group, Inc.

Founded in 2017, LifeStance (Nasdaq: LFST) is reimagining mental health. We are one of the nation’s largest providers of virtual and in-person outpatient mental healthcare for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable, and personalized mental healthcare. LifeStance and its supported practices employ over 8,800 psychiatrists, advanced practice nurses, psychologists and therapists and operates across 35 states and more than 575 centers. To learn more, please visit www.LifeStance.com.

We routinely post information that may be important to investors on the “Investor Relations” section of our website at investor.lifestance.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Financial statements

Income Statement

Three Months Ended September 30, — (In thousands, except per share amounts)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
TOTAL REVENUE455,864363,8091,294,6941,042,090
OPERATING EXPENSES
Center costs, excluding depreciation and amortization shown separately below294,462247,227844,319707,286
General and administrative expenses113,38995,615321,858287,421
Depreciation and amortization14,93613,55742,50341,319
Total operating expenses422,787356,3991,208,6801,036,026
INCOME FROM OPERATIONS33,0777,41086,0146,064
OTHER EXPENSE
Loss on remeasurement of contingent consideration-2,339-2,370
Transaction costs-510-1,499
Interest expense, net-2,491-2,814-6,916-8,787
Other expense-334-24-609-117
Total other expense-5,674-2,838-11,394-8,904
INCOME (LOSS) BEFORE INCOME TAXES27,4034,57274,620-2,840
INCOME TAX (PROVISION) BENEFIT-5,018-3,495-14,380835
NET INCOME (LOSS)22,3851,07760,240-2,005
EARNINGS (LOSS) PER SHARE
Basic0.0600.16-0.01
Diluted0.0600.15-0.01
Weighted-average shares outstanding
Basic381,214386,963383,976385,672
Diluted391,223388,895391,180385,672
NET INCOME (LOSS)22,3851,07760,240-2,005
OTHER COMPREHENSIVE LOSS
Unrealized losses on cash flow hedge, net of tax-345-929
COMPREHENSIVE INCOME (LOSS)22,38573260,240-2,934

Income Statement

Three Months Ended September 30, — FROM OPERATIONS TO CENTER MARGIN (in thousands)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Income from operations33,0777,41086,0146,064
Adjusted for:
Depreciation and amortization14,93613,55742,50341,319
General and administrative expenses (1)113,38995,615321,858287,421
Center Margin161,402116,582450,375334,804

Income Statement

Three Months Ended September 30, — TO ADJUSTED EBITDA (in thousands)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net income (loss)22,3851,07760,240-2,005
Adjusted for:
Interest expense, net2,4912,8146,9168,787
Depreciation and amortization14,93613,55742,50341,319
Income tax provision (benefit)5,0183,49514,380-835
Loss on remeasurement of contingent consideration2,3392,370
Stock-based compensation expense18,16818,29753,11757,997
Loss on disposal of assets33424609117
Transaction costs (1)5101,499
Executive transition costs5771,296
Litigation costs (2)34-70-941,088
Strategic initiatives (3)1,7412,738
Real estate optimization and restructuring charges (4)-27-6-38-103
Amortization of cloud-based software implementation costs (5)4284441,2691,199
Adjusted EBITDA68,35740,209185,509108,860

Balance Sheet

September 30, 2026 — (In thousands, except for par value)

September 30, 2026December 31, 2025
CURRENT ASSETS
Cash and cash equivalents218,818248,642
Patient accounts receivable, net120,94095,710
Prepaid expenses and other current assets37,02171,848
Total current assets376,779416,200
NONCURRENT ASSETS
Property and equipment, net166,428161,583
Right-of-use assets162,395149,720
Intangible assets, net170,041177,665
Goodwill1,305,3891,293,346
Other noncurrent assets5,2515,419
Total noncurrent assets1,809,5041,787,733
Total assets2,186,2832,203,933
CURRENT LIABILITIES
Accounts payable5,5026,122
Accrued payroll expenses129,848143,327
Other accrued expenses60,09942,187
Operating lease liabilities, current45,03945,544
Other current liabilities20,64114,782
Total current liabilities261,129251,962
NONCURRENT LIABILITIES
Long-term debt, net255,524265,927
Operating lease liabilities, noncurrent160,458148,553
Deferred tax liability, net16,40816,408
Other noncurrent liabilities37368
Total noncurrent liabilities432,763430,956

Cash Flow

Nine Months Ended September 30, — (In thousands)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss)60,240-2,005
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization42,50341,319
Non-cash operating lease costs32,69431,265
Stock-based compensation53,11757,997
Amortization of discount and debt issue costs758762
Other, net4,3561,440
Change in operating assets and liabilities, net of businesses acquired:
Patient accounts receivable, net-24,38110,729
Prepaid expenses and other current assets33,546-10,410
Accounts payable-5132,868
Accrued payroll expenses-14,146-3,689
Operating lease liabilities-34,116-35,829
Other accrued expenses15,979-5,856
Net cash provided by operating activities170,03788,591
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment-37,415-25,214
Acquisitions of businesses, net of cash acquired-9,590
Net cash used in investing activities-47,005-25,214
CASH FLOWS FROM FINANCING ACTIVITIES
Payments of long-term debt-10,875-5,438
Taxes related to net share settlement of equity awards-24,919-8,607
Proceeds from the exercise of stock options5,368
Repurchases of common stock-122,430
Net cash used in financing activities-152,856-14,045
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS-29,82449,332
Cash and cash equivalents - beginning of period248,642154,571
CASH AND CASH EQUIVALENTS – END OF PERIOD218,818203,903
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest, net12,29813,253
Cash paid for taxes, net of refunds1,2941,564
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Contingent consideration incurred in acquisitions of businesses3,983$—
Acquisition of property and equipment included in liabilities4,5464,484

Income Statement (in millions)

Q3 2026Q3 2025Y/Y
(in millions)
Total revenue455.9363.825.0%
Income from operations33.17.4
Center Margin161.4116.638.0%
Net income22.41.1
Adjusted EBITDA68.440.270.0%
As % of Total revenue:
Income from operations7.32
Center Margin35.432
Net income4.90.3
Adjusted EBITDA1511.1

Forward-Looking Statements... (truncated)essions as they relate to us are intended to identify forward-looking statements. They involve a number of risks and uncertainties that may cause actual events and results to differ materially from such forward-looking statements. These risks and uncertainties include, but are not limited to: if reimbursement rates paid by third-party payors are reduced or if third-party payors otherwise restrain our ability to obtain or deliver care to patients, our business could be materially harmed; we may not grow at the rates we historically have achieved or at all, even if our key metrics may imply future growth, including if we are unable to successfully execute on our growth initiatives and business strategies; if we fail to manage our growth effectively, our expenses could increase more than expected, our revenue may not increase proportionally or at all, and we may be unable to execute on our business strategy; our ability to recruit new clinicians and retain existing clinicians; we conduct business in a heavily regulated industry and if we fail to comply with these laws and government regulations, we could incur penalties or be required to make significant changes to our operations or experience adverse publicity, which could have a material adverse effect on our business, results of operations and financial condition; we are dependent on our relationships with supported practices, which we do not own, to provide healthcare services, and our business would be harmed if those relationships were disrupted or if our arrangements with these entities became subject to legal challenges; we operate in a competitive industry, and if we are not able to compete effectively, our business and financial performance would be harmed; the impact on us of healthcare reform legislation and other changes in the healthcare industry and in healthcare spending is currently unknown, but may harm our business; if our or our vendors’ security measures fail or are breached and unauthorized access to our employees’, patients’ or partners’ data is obtained, our systems may be perceived as insecure, we may incur significant liabilities, including through private litigation or regulatory action, our reputation may be harmed, and we could lose patients and partners; our business depends on our ability to effectively invest in, implement improvements to and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems; our existing indebtedness could adversely affect our business and growth prospects; and other risks and uncertainties set forth under “Risk Factors” included in the reports we have filed or will file with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent filings made with the Securities and Exchange Commission. LifeStance does not undertake to update any forward-looking statements made in this press release to reflect any change in management's expectations or any change in the assumptions or circumstances on which such statements are based, except as otherwise required by law.

Non-GAAP Financial Information

This press release contains certain non-GAAP financial measures, including Center Margin, Adjusted EBITDA, and Adjusted EBITDA margin. Tables showing the reconciliation of these non-GAAP financial measures to the comparable GAAP measures are included at the end of this release. Management believes these non-GAAP financial measures are useful in evaluating the Company’s operating performance, and may be helpful to securities analysts, institutional investors and other interested parties in understanding the Company’s operating performance and prospects. This press release also refers to Free Cash Flow, which is calculated as net cash provided by operating activities less purchases of property and equipment. Management believes Free Cash Flow is a useful indicator of liquidity that provides information to management and investors about the amount of cash generated from our operations that, after investments in property and equipment, can be used for future growth. These non-GAAP financial measures, as calculated, may not be comparable to companies in other industries or within the same industry with similarly titled measures of performance. Therefore, the Company’s non-GAAP financial measures should be considered in addition to, not as a substitute for, or in isolation from, measures prepared in accordance with GAAP, such as net income (loss) or income from operations.

Center Margin and Adjusted EBITDA anticipated for the fourth quarter of 2026 and full year 2026 are calculated in a manner consistent with the historical presentation of these measures at the end of this release. Reconciliation for the forward-looking fourth quarter of 2026 and full year 2026 Center Margin, Adjusted EBITDA guidance and Free Cash Flow is not being provided, as LifeStance does not currently have sufficient data to accurately estimate the variables and individual adjustments for such reconciliation. As such, LifeStance management cannot estimate on a forward-looking basis without unreasonable effort the impact these variables and individual adjustments will have on its reported results.

Management acknowledges that there are many items that impact a company’s reported results and the adjustments reflected in these non-GAAP measures are not intended to present all items that may have impacted these results.

# # # #

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.